Literature DB >> 8360126

Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

I Odenholt-Tornqvist1.   

Abstract

The postantibiotic effect (PAE), the postantibiotic sub-MIC effect (PA SME) and the sub-MIC effect (SME) of a new carbapenem, meropenem, were determined for different strains of Escherichia coli and Pseudomonas aeruginosa. A PAE was induced by 10 x MIC of meropenem for 2 h. After induction, the antibiotic was eliminated by washing and dilution. The strains in the postantibiotic exposure phase and the controls were then exposed to no antibiotic or to different sub-MICs concentrations (0.1-0.6 x MIC) of meropenem. The growth curves were followed for 24 h with viable counts and/or measured by continuous monitoring of optical density in a BioScreen C apparatus. Zero or very low values for the PAE were seen in the strains studied. However, a long PA SME and SME were seen for P. aeruginosa when determined by both methods, which at 0.3 x MIC gave comparable results. At lower concentrations the PA SMEs measured with BioScreen C were shorter, probably due to differences in the definition between the two methods. The BioScreen C method was less laborious than viable counting. However, one disadvantage of the BioScreen C method was that manual viable counting still had to be used to determine bacterial killing. No PA SME or SME against E. coli was observed, and the increased sensitivity of P. aeruginosa to sub-MICs of carbapenems remains unexplained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360126     DOI: 10.1093/jac/31.6.881

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  37 in total

1.  Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.

Authors:  S K Spangler; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Pharmacodynamic parameters of aminoglycosides and their effect on exoenzymes of Pseudomonas aeruginosa.

Authors:  A Hostacká
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

3.  Deletion of the multiple-drug efflux pump AcrAB in Escherichia coli prolongs the postantibiotic effect.

Authors:  William Stubbings; Julieanne Bostock; Eileen Ingham; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Postantibiotic effect of DX-619 against 16 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

6.  Postantibiotic effects of telavancin against 16 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

7.  Postantibiotic effects of imipenem and enoxacin against S. typhimurium and S. enteritidis and the influence on their surface hydrophobicity.

Authors:  L Majtánová; V Majtán
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

8.  Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.